A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2012
At a glance
- Drugs Fostamatinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms SOLEIL
- 07 Jun 2011 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 20 May 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Dec 2008 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.